CCM
VIR icon

Connective Capital Management’s Vir Biotechnology VIR Stock Holding History

Connective Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75,470
Closed -$431K – 88
2025
Q3 		$431K Buy
+75,470
New +$386K 0.4% 37

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Connective Capital Management's VIR Position: Q4 2025 in Review

Connective Capital Management sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 75,470 shares — an estimated $431K sold.

Connective Capital Management first reported a position in VIR in Q3 2025 and held it in 1 quarter. The position peaked at $431K in Q3 2025. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • Connective Capital Management reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Connective Capital Management sold 75,470 Vir Biotechnology shares in Q4 2025, an estimated $431K.
  • Connective Capital Management first reported a position in Vir Biotechnology in Q3 2025 and held it in 1 quarter.
  • Connective Capital Management's Vir Biotechnology position peaked at $431K in Q3 2025.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Connective Capital Management's 13F filing for Q4 2025, filed 19 Feb 2026.